By: Dr Zaid Matti
Musculoskeletal Medicine Specialist

If you're living with joint pain, a stubborn tendon injury, or early arthritis, you've probably been told your options are some combination of painkillers, physiotherapy, cortisone injections, or — eventually — surgery. For many people, those work. For many others, they don't, or they only help for a while.

Over the past decade, a different approach has been quietly building an evidence base: orthobiologics. Rather than masking pain or replacing a worn joint, these treatments aim to support your body's own ability to heal. This guide explains what they are, how they work, and what the research actually says — without the hype.

What are orthobiologics?

"Ortho" means bone and joint. "Biologics" means treatments made from biological material — usually your own blood, bone marrow, or fat. Put together, orthobiologics are treatments that use naturally occurring cells, proteins, and signalling molecules to help injured or worn-out tissues recover.

The goal is to:

1. Slow down the wear and tear in arthritic joints
2. Help tendons, ligaments, and soft tissues repair
3. Calm chronic inflammation
4. Reduce long-standing pain
5. Give your body's natural healing the best chance to do its job

Importantly, orthobiologics don't replace surgery when surgery is genuinely needed. But for many patients, they offer a meaningful option in between "wait and see" and "operate."

The main orthobiologic treatments

1. Platelet-rich plasma (PRP)

What it is: A small sample of your own blood is taken (similar to a routine blood test) and spun in a centrifuge. This separates out the platelets — tiny cells in your blood that are central to healing — and concentrates them. The concentrate is then injected into the painful joint or tendon.

How it works: Platelets release growth factors — chemical messengers that tell your body to repair tissue, build new collagen, and form fresh blood supply. They also help calm inflammation.

What the research shows:

1. Knee osteoarthritis: A large 2021 study published in JAMA showed PRP improved symptoms at 12 months compared with placebo (Bennell et al., 2021). An earlier review found PRP outperformed hyaluronic acid (the "gel injection") for both pain and function (Shen et al., 2017).
2. Tennis elbow, rotator cuff, and Achilles tendinopathy: PRP reduced pain significantly more than placebo or cortisone injections (Fitzpatrick et al., 2017).
3. Rotator cuff (shoulder): PRP improved both pain and function (Hurley et al., 2021).

Bottom line: PRP is the most studied orthobiologic, with good evidence in knee arthritis and several tendon problems.

2. Alpha-2-macroglobulin (A2M)

What it is: A2M is a large protein that already exists in your blood. It's been called a "molecular trap" — it binds to and neutralises the destructive enzymes that chew through cartilage in early arthritis.

How it works: In an arthritic joint, certain enzymes (called MMPs) and inflammatory signals (IL-1, TNF-α) accelerate cartilage breakdown. A2M can soak these up, slowing the process.

What the research shows: Laboratory and early clinical studies suggest A2M is a promising adjunct for early-stage arthritis (Kraus et al., 2017; Lodhia et al., 2021). The evidence base is smaller than PRP's, but mechanistically it's well understood.

Bottom line: Useful as a targeted option in early osteoarthritis, often combined with other treatments.

3. Bone marrow aspirate concentrate (BMAC)

What it is: A sample of bone marrow is drawn from the iliac crest (the top of your pelvis) under local anaesthetic. The marrow is concentrated to capture mesenchymal stem cells (MSCs), platelets, and growth factors, then injected into the damaged area.

How it works: MSCs are versatile cells that can support cartilage repair, regulate the immune system, and reduce inflammation. They act partly by becoming new tissue, but mostly by signalling to the surrounding cells to heal.

What the research shows:

1. Improvement in pain and function in knee osteoarthritis (Centeno et al., 2018).
2. Evidence of cartilage repair in early arthritis (Kim et al., 2014).
3. Strong clinical potential, though protocols still vary between providers (Chahla et al., 2016).

Bottom line: A solid option for moderate to advanced arthritis, particularly when patients want to delay or avoid joint replacement. Technique matters — a lot — so the experience of the operator counts.

4. Adipose-derived mesenchymal stem cells (AD-MSCs)

What it is: Fat tissue is one of the richest natural sources of stem cells in the body. A small amount is harvested (similar to a mini-liposuction), then either minimally processed or culture-expanded in a laboratory to grow large numbers of stem cells before injection.

How it works: AD-MSCs are powerful regulators of inflammation and immune response. They protect cartilage, reduce inflammatory signals, and support tissue repair.

What the research shows:

1. Significant improvements in knee arthritis pain and function (Freitag et al., 2019).
2. Evidence of cartilage regeneration in severe arthritis (Jo et al., 2014).
3. Long-term benefit demonstrated in advanced knee arthritis (Lee et al., 2019).

Bottom line: One of the most promising options for moderate to severe arthritis, particularly for patients hoping to delay joint replacement. The evidence is still evolving, and not every clinic offers culture-expanded preparations — which is the form most of the published research uses.

5. Exosomes and birth-tissue-derived products

What they are: Exosomes are tiny vesicles released by cells, carrying signalling molecules (proteins, lipids, RNA fragments) that influence repair in surrounding tissue. Birth-tissue products (such as those derived from umbilical cord or placental tissue, where regulations permit) contain a mix of growth factors and similar signalling molecules.

Where the science is at: This is genuinely exciting research, but it's early. Most of the evidence is from laboratory and animal studies, with limited high-quality human trials so far (Mendt et al., 2019). Regulatory frameworks for these products vary widely between countries.

Bottom line: Promising, but not yet a routine clinical option. Be cautious of clinics marketing these as established treatments.

Why orthobiologics matter

Orthobiologics aren't a replacement for good orthopaedic care, and they aren't a miracle. What they can do, when used appropriately, is:

1. Delay surgery — sometimes by years, sometimes indefinitely.
2. Improve pain and movement when conventional treatments have plateaued.
3. Slow the progression of joint and tendon degeneration.
4. Activate your body's own healing rather than override it.

Each treatment needs to be matched carefully to:

1. The condition and how advanced it is
2. Your overall health, age, and activity goals
3. What the evidence actually supports for your specific problem
4. Safe, regulated, evidence-informed protocols

Are orthobiologics right for me?

The honest answer: it depends. Orthobiologics work best when chosen for the right person, the right tissue, and the right stage of disease. They're not appropriate for everyone, and no responsible clinician will promise a fixed outcome.

If you're considering these treatments, look for a clinician who:

1. Holds formal training in musculoskeletal or regenerative medicine
2. Will examine you and review your imaging properly before recommending anything
3. Discusses the evidence alongside the option, including its limits
4. Doesn't oversell

If you'd like to discuss whether an orthobiologic option might suit your situation, you're welcome to book a consultation.

References

1. Bennell KL et al. JAMA. 2021;326(20):2021–2030.
2. Shen L et al. Arthroscopy. 2017;33(3):659–670.
3. Fitzpatrick J et al. Am J Sports Med. 2017;45(1):226–233.
4. Hurley ET et al. Arthroscopy. 2021;37(3):1193–1205.
5. Kraus VB et al. Osteoarthritis Cartilage. 2017;25(8):1233–1240.
6. Lodhia P et al. Am J Orthop. 2021;50(6):279–285.
7. Centeno CJ et al. Stem Cells Int. 2018;2018:6150987.
8. Kim JD et al. Am J Sports Med. 2014;42(8):1764–1773.
9. Chahla J et al. Arthroscopy. 2016;32(6):1151–1167.
10. Freitag J et al. Stem Cells Int. 2019;2019:4313565.
11. Jo CH et al. Stem Cells. 2014;32(5):1254–1266.
12. Lee WS et al. Stem Cells Int. 2019;2019:2715291.
13. Mendt M et al. Cell Stem Cell. 2019;25(5):724–740.